Private investment fills gap in US cancer research amid federal budget cuts.

Private investment in oncology ventures has increased, with companies such as Oncolytics Biotech Inc., ImmunityBio, Inc., Agenus Inc., Sutro Biopharma, Inc., and Castle Biosciences, Inc. securing hundreds of millions in funding. The Senate restored $15 million for the Pancreatic Cancer Research Program, but federal budget cuts have put pressure on cancer research efforts. Investors are focusing on companies with standout science, solid pipelines, and clear regulatory strategies.

Private investment in oncology ventures has surged, with companies like Oncolytics Biotech Inc., ImmunityBio, Inc., Agenus Inc., Sutro Biopharma, Inc., and Castle Biosciences, Inc. securing hundreds of millions in funding. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) provided a glimmer of hope, but federal budget cuts continue to put pressure on cancer research efforts [1]. Despite these challenges, investors are focusing on companies with standout science, solid pipelines, and clear regulatory strategies.

Oncolytics Biotech Inc. (NASDAQ: ONCY) has emerged as a key player in the oncology landscape. The company has reached a pivotal inflection point, advancing toward a registration-enabling trial for its breakthrough immunotherapy, pelareorep, in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). Pelareorep, a systemically delivered oncolytic virus, transforms immunologically "cold" tumors into "hot" targets responsive to immune-based treatments. Clinical data reveals pelareorep combinations achieved a remarkable 21.9% two-year overall survival rate in first-line pancreatic cancer patients, substantially outperforming the 9.2% historical benchmark established by standard chemotherapy protocols [1].

ImmunityBio, Inc. (NASDAQ: IBRX) has also made significant strides. The company reported groundbreaking results in its pilot study for recurrent glioblastoma, achieving 100% disease control in all five patients treated with its investigational immune-boosting regimen combining ANKTIVA, NK cell therapy, and Optune Gio Tumor Treating Fields [1]. Three of the five patients responded to treatment, with two achieving near complete responses while the remaining two maintained stable disease in this chemotherapy-free approach.

Agenus Inc. (NASDAQ: AGEN) is advancing its botensilimab (BOT) and balstilimab (BAL) immunotherapy combination, which delivered 42% two-year survival in refractory MSS colorectal cancer. The company secured regulatory alignment for its Phase 3 BATTMAN trial initiation in Q4 2025 and expects a $91 million capital infusion from Zydus Lifesciences collaboration upon closing [1].

Sutro Biopharma, Inc. (NASDAQ: STRO) delivered exceptional revenue growth in the second quarter of 2025, reporting $63.7 million compared to $25.7 million in Q2 2024, driven primarily by the Astellas collaboration and recognition of previously deferred revenue from Ipsen's decision not to advance the STRO-003 program [1].

These developments underscore the resilience and innovation within the oncology sector, despite the challenges posed by federal budget cuts. The focus on companies with robust survival data and clear regulatory strategies highlights the market's confidence in the potential of these ventures to transform cancer treatment.

References:

[1] https://www.prnewswire.com/news-releases/fda-tightens-survival-standards-as-cancer-drug-pipeline-hits-866b-market-milestone-302541223.html